This company is no longer active
Zosano Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$13.53m |
Equity | US$14.05m |
Total liabilities | US$12.39m |
Total assets | US$26.45m |
Recent financial health updates
Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?
Nov 02Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?
Jun 29Recent updates
Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?
Nov 02Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?
Jun 29Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%
May 26Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech
Apr 30Zosano shares rise on migraine treatment NDA resubmission update
Apr 26Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)
Mar 15Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine
Feb 01Zosano Pharma requests FDA meeting for its Qtrypta application
Jan 04Zosano Pharma EPS misses by $0.01
Nov 13Financial Position Analysis
Short Term Liabilities: ZSAN.Q's short term assets ($15.6M) exceed its short term liabilities ($9.7M).
Long Term Liabilities: ZSAN.Q's short term assets ($15.6M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: ZSAN.Q is debt free.
Reducing Debt: ZSAN.Q has no debt compared to 5 years ago when its debt to equity ratio was 39.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZSAN.Q has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ZSAN.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year